J&J, Roche, Celgene and others power new cancer-drug wave

In the world of cancer drugs, calling a new entry "the next Avastin" or "the next Gleevec" is like picking out the next Brad Pitt or the next Beyoncé. Those two treatments were among a crop of future blockbusters launched as the new millennium kicked into gear, and they're top sellers today. But that's just what the IMS Institute for Healthcare Informatics is doing in its latest report on the pharma business. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.